uniQure - QURE Stock Forecast, Price & News

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure Stock Performance

NASDAQ:QURE traded up $0.48 during trading hours on Wednesday, hitting $19.50. The company's stock had a trading volume of 15,119 shares, compared to its average volume of 612,025. uniQure has a 12 month low of $12.52 and a 12 month high of $38.80. The company's 50 day simple moving average is $19.82 and its two-hundred day simple moving average is $17.64. The company has a market cap of $909.64 million, a P/E ratio of 2.78 and a beta of 1.01. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.94 and a quick ratio of 12.94.

Analysts Set New Price Targets

A number of brokerages recently commented on QURE. Chardan Capital dropped their price target on uniQure from $65.00 to $60.00 and set a "buy" rating for the company in a research note on Tuesday. Truist Financial decreased their price objective on uniQure from $90.00 to $51.00 in a report on Wednesday, April 13th. The Goldman Sachs Group decreased their price objective on uniQure from $59.00 to $51.00 and set a "buy" rating for the company in a report on Tuesday, May 24th. Wells Fargo & Company decreased their price objective on uniQure from $34.00 to $24.00 and set an "equal weight" rating for the company in a report on Tuesday. Finally, StockNews.com upgraded uniQure from a "sell" rating to a "hold" rating in a report on Wednesday, June 8th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, uniQure has an average rating of "Moderate Buy" and an average price target of $48.38.

Insider Buying and Selling

In related news, VP Alexander Edward Kuta III sold 27,358 shares of uniQure stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $25.00, for a total value of $683,950.00. Following the completion of the sale, the vice president now directly owns 95,196 shares in the company, valued at approximately $2,379,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other uniQure news, COO Pierre Caloz sold 7,575 shares of the firm's stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $13.21, for a total value of $100,065.75. Following the transaction, the chief operating officer now directly owns 64,511 shares of the company's stock, valued at $852,190.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Alexander Edward Kuta III sold 27,358 shares of the firm's stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $25.00, for a total value of $683,950.00. Following the completion of the transaction, the vice president now directly owns 95,196 shares in the company, valued at $2,379,900. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,263 shares of company stock worth $947,359. 3.10% of the stock is owned by corporate insiders.